NCT00090116已完成3 期
A Randomized, Double-Blind,Placebo-Controlled Evaluation of the Safety and Efficacy of Neramexane Monotherapy in Patients With Moderate to Severe Dementia of the Alzheimer's Type
Forest Laboratories68 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2003年3月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 400
- 试验地点
- 68
研究概览
简要总结
Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells through interaction with a certain type of receptor (N-methyl-D-aspartate, NMDA) on the cell. Neramexane is a new drug that blocks the effects of excessive glutamate at the receptor (NMDA receptor antagonist).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of moderate to severe Alzheimer's disease;
- •ambulatory patients
排除标准
- •folate deficiency;
- •clinically significant central nervous system disease other than Alzheimer's disease;
- •clinically significant pulmonary, gastrointestinal, renal, hepatic, endocrine or cardiovascular disease
研究者
研究点 (68)
Loading locations...
相似试验
已完成
不适用
Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's DiseaseModerate Alzheimer's DiseaseNCT00423228Debiopharm International SA228
已完成
1 期
Bisnorcymserine in Healthy Adult VolunteersHealthy VolunteersNCT01747213National Institute on Aging (NIA)75
Unknown
不适用
The Treatment of High Intensity Transcranial Current Stimulation for Alzheimer's DiseaseMild Cognitive ImpairmentDementiaAlzheimer's DiseaseNCT06380725Anhui Provincial Hospital60
Unknown
不适用
Modulation of Cognition and Brain Connectivity by Noninvasive Brain Stimulation in Patients With Mild Cognitive Impairment Due to Alzheimer's DiseaseMild Cognitive ImpairmentNCT04012346Masaryk University20
已完成
2 期
Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)Mild Cognitive Impairment Due to Alzheimer's DiseaseAlzheimer's Disease, Early OnsetNCT06182085PRInnovation GmbH304